134 related articles for article (PubMed ID: 32434198)
1. [mHSPC-Therapie mit Apalutamid/ADT].
Bismarck E; Hammerer P; Merseburger AS; Schrader AJ
Oncol Res Treat; 2020; 43 Suppl 2():6-12. PubMed ID: 32434198
[No Abstract] [Full Text] [Related]
2. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
[TBL] [Abstract][Full Text] [Related]
3. Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Ito T; Grant L; Duckham BR; Ribbands AJ; Gater A
Adv Ther; 2018 Dec; 35(12):2186-2200. PubMed ID: 30415297
[TBL] [Abstract][Full Text] [Related]
4. SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).
Omrčen T
Acta Clin Croat; 2022 Oct; 61(Suppl 3):81-85. PubMed ID: 36938560
[TBL] [Abstract][Full Text] [Related]
5. Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.
Hall F; de Freitas HM; Kerr C; Ito T; Nafees B; Lloyd AJ; Penton J; Hadi M; Lanar S; Pham TP
Qual Life Res; 2019 May; 28(5):1191-1199. PubMed ID: 30767088
[TBL] [Abstract][Full Text] [Related]
6. Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China.
Liu M; Qu S; Liu Y; Yao X; Jiang W
J Comp Eff Res; 2019 Aug; 8(11):865-877. PubMed ID: 31476895
[No Abstract] [Full Text] [Related]
7. [Vorwort].
von Amsberg G; Gschwend JE
Oncol Res Treat; 2020; 43 Suppl 2():5. PubMed ID: 32428911
[No Abstract] [Full Text] [Related]
8. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
[TBL] [Abstract][Full Text] [Related]
9. Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
Tan PS; Aguiar P; Haaland B; Lopes G
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):516-523. PubMed ID: 29875432
[TBL] [Abstract][Full Text] [Related]
10. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
[TBL] [Abstract][Full Text] [Related]
11. Hormone naïve metastatic prostate cancer: How to treat it?
Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
[TBL] [Abstract][Full Text] [Related]
12. The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy.
Barata P; Swami U; Agarwal N
Expert Rev Anticancer Ther; 2020 Mar; 20(3):147-150. PubMed ID: 32068456
[No Abstract] [Full Text] [Related]
13. Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Baston C; Preda A; Guler-Margaritis SS; Sinescu I; Gingu C
Curr Opin Urol; 2020 Jul; 30(4):576-583. PubMed ID: 32427630
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
Messina C; Messina M; Boccardo F
Eur Urol; 2018 Jan; 73(1):147-148. PubMed ID: 28801126
[No Abstract] [Full Text] [Related]
15. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
[TBL] [Abstract][Full Text] [Related]
17. [Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?].
Thomas C; Ohlmann CH
Urologe A; 2020 Jun; 59(6):665-672. PubMed ID: 32274544
[TBL] [Abstract][Full Text] [Related]
18. [Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial].
von Amsberg G
Urologe A; 2020 Jun; 59(6):723-724. PubMed ID: 32240319
[No Abstract] [Full Text] [Related]
19. Treatment of hormone-naïve metastatic prostate cancer.
Hamilou Z; Saad F; Fizazi K
Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
[TBL] [Abstract][Full Text] [Related]
20. Clinical and basic research implications of the article 'IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer'.
Heidegger I; Culig Z
Endocr Relat Cancer; 2024 May; 31(5):. PubMed ID: 38442006
[No Abstract] [Full Text] [Related]
[Next] [New Search]
